Bexarotene prodrugs: Targeting through cleavage by NQO1 (DT-diaphorase)
A Schäfer, ES Burstein, R Olsson
Index: Schaefer, Anja; Burstein, Ethan S.; Olsson, Roger Bioorganic and Medicinal Chemistry Letters, 2014 , vol. 24, # 8 p. 1944 - 1947
Full Text: HTML
Citation Number: 8
Abstract
Abstract Bexarotene, a retinoid X receptor (RXR) agonist, is being tested as a potential disease modifying treatment for neurodegenerative conditions. To limit the peripheral exposure of bexarotene and release it only in the affected areas of the brain, we designed a prodrug strategy based on the enzyme NAD (P) H/quinone oxidoreductase (NQO1) that is elevated in neurodegenerative diseases. A series of indolequinones (known substrates of ...
Related Articles:
[Cotterill, Ann S.; Moody, Christopher J.; Mortimer, Roger J.; Norton, Claire L.; O'Sullivan, Noeleen; et al. Journal of Medicinal Chemistry, 1994 , vol. 37, # 22 p. 3834 - 3843]
[Naylor, Matthew A.; Swann, Elizabeth; Everett, Steven A.; Jaffar, Mohammed; Nolan, John; Robertson, Naomi; Lockyer, Stacey D.; Patel, Kantilal B.; Dennis, Madeleine F.; Stratford, Michael R. L.; Wardman, Peter; Adams, Gerald E.; Moody, Christopher J.; Stratford, Ian J. Journal of Medicinal Chemistry, 1998 , vol. 41, # 15 p. 2720 - 2731]
[Cotterill, Ann S.; Moody, Christopher J.; Mortimer, Roger J.; Norton, Claire L.; O'Sullivan, Noeleen; et al. Journal of Medicinal Chemistry, 1994 , vol. 37, # 22 p. 3834 - 3843]
[Cotterill, Ann S.; Moody, Christopher J.; Mortimer, Roger J.; Norton, Claire L.; O'Sullivan, Noeleen; et al. Journal of Medicinal Chemistry, 1994 , vol. 37, # 22 p. 3834 - 3843]
[Beall, Howard D.; Winski, Shannon; Swann, Elizabeth; Hudnott, Anna R.; Cotterill, Ann S.; O'Sullivan, Noeleen; Green, Stephen J.; Bien, Richard; Siegel, David; Ross, David; Moody, Christopher J. Journal of Medicinal Chemistry, 1998 , vol. 41, # 24 p. 4755 - 4766]